The DLGAP4 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human DLGAP4 gene in HT29 colorectal adenocarcinoma cells. This heterogeneous pool provides a robust loss-of-function model for assessing DLGAP4 function without clonal selection bias. Supplied as a polyclonal population, it enables evaluation of collective DLGAP4 ablation effects on cellular phenotypes.
HT29 is an adherent epithelial colorectal adenocarcinoma cell line derived from the primary tumor of a 44-year-old female. It is a widely used model for colorectal cancer biology, epithelial barrier function, and differentiation studies. The cell line exhibits canonical Wnt pathway dysregulation, making it relevant for investigating Wnt/??-catenin signaling components. Its adherent growth properties also support assays for cell adhesion, migration, and drug response.
DLGAP4 encodes SAPAP4, a postsynaptic scaffold protein that organizes synaptic signaling and the cytoskeleton through interactions with DLG4 (PSD-95) and SHANK proteins. Beyond neurons, it regulates the actin cytoskeleton and Wnt/??-catenin signaling. DLGAP4 forms complexes with SHANK1/2/3, DLGAP1, HOMER1, and CTNNB1, linking cell surface receptors to intracellular networks. It is regulated by NMDA receptor signaling, Wnt ligands, and CaM kinases, and its downstream effects include actin remodeling, SHANK-mediated signaling, and transcription of Wnt targets MYC and CCND1. In HT29 cells, DLGAP4 disruption may impair Wnt activity and weaken cell adhesion, contributing to cancer phenotypes.
Combining DLGAP4 scaffolding roles with the aberrant Wnt signaling of HT29 cells creates a platform to dissect colorectal cancer mechanisms. DLGAP4 loss is expected to alter adhesion, migration, and proliferation, facilitating tumorigenesis studies. This model uniquely bridges synaptic scaffold biology and epithelial cancer, allowing exploration of adherens junction?CWnt crosstalk in a relevant genetic context.
Applications include functional characterization of DLGAP4, colorectal cancer cell biology, and translational research. Assays such as immunofluorescence, RNA-seq, western blotting, scratch wound healing, and cell adhesion assays evaluate the impact of DLGAP4 loss. Wnt pathway studies employ TOP/FOP reporter assays, while MTT and flow cytometry assess proliferation and apoptosis. Drug sensitivity screening against 5-fluorouracil and oxaliplatin is also supported. For further information, contact Ascent Research.
